Dxd NEW
| Price | $39 | $68 | $97 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-09-10 |
Product Details
| Product Name: Dxd | CAS No.: 1599440-33-1 |
| Purity: 99.49% | Supply Ability: 10g |
| Release date: 2026/09/10 |
Product Introduction
Bioactivity
| Name | Dxd |
| Description | Dxd (OQM5SD32BQ) is a potent DNA topoisomerase I inhibitor (IC50= 0.31 μM). Dxd was used as a conjugate drug for HER2-targeted ADCs. |
| In vitro | Method: Human cancer cell lines KPL-4, NCI-N87, SK-BR-3 and MDA-MB-468, HER2-positive KPL-4, NCI-N87 and SK-BR-3 cell lines, and MDA-MB-468 cell lines were treated with Dxd for 6 days. Cell viability was measured using CellTiter-Glo luminescent cell viability assay reagent. Result: Dxd showed cytotoxicity against human cancer cell lines KPL-4, NCI-N87, SK-BR-3, and MDA-MB-468 with IC50 of 1.43 nm-4.07 nM ng/mL. Dxd significantly inhibited HER2 positive KPL-4, NCI-N87 and SK-BR-3 cell lines with IC50 of 26.8, 25.4 and 6.7 ng/mL, respectively. However, no such inhibitory effect was observed in MDA-MB-468 cells treated with Dxd (IC50 >10000 ng/mL). [1] |
| In vivo | Method: To investigate the antitumor activity of Dxd, DS-8201a (Dxd as payload) (10 mg/kg) was injected intravenously in a HER2-positive mouse model with KPL4, JIMT-1, and Capan-1 and in HER2 low expression ST565 vs Mouse model of ST313 with a single injection. Result: Dxd showed potent antitumor activity. [1] |
| Storage | Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 5.15 mg/mL (10.44 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. H2O : insoluble 10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline : 5.15 mg/mL (10.44 mM), Solution. DMSO : 51.50 mg/mL (104.36 mM), Sonication is recommended. |
| Keywords | Topoisomerase I | Topoisomerase | Inhibitor | inhibit | HER2-targeting | Dxd | Camptothecins | ADCCytotoxin | ADC Payload | ADC Cytotoxin | ADC |
| Inhibitors Related | Ciprofloxacin hydrochloride monohydrate | Levofloxacin hydrochloride | Norfloxacin | Anthraquinone | Methotrexate disodium | Prulifloxacin | 1,4-Naphthoquinone | Ofloxacin | Levofloxacin | Dexamethasone | 3-Hydroxypyridine | Etoposide |
| Related Compound Libraries | Bioactive Compounds Library Max | DNA Damage & Repair Compound Library | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:303137-03-3
-
-
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY